ArticleBMC cancer2024

Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.

Meng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.